tiprankstipranks
Advertisement
Advertisement

ATOS Stock Latest News

Atossa Therapeutics initiated with a Buy at Rodman & Renshaw
The FlyAtossa Therapeutics initiated with a Buy at Rodman & Renshaw
5d ago
ATOS
Atossa Therapeutics Announces Registered Direct Offering and Warrants
PremiumCompany Announcements
Atossa Therapeutics Announces Registered Direct Offering and Warrants
1M ago
8K
ATOS
Atossa Therapeutics announces registered direct offering of up to $16.5M
PremiumThe Fly
Atossa Therapeutics announces registered direct offering of up to $16.5M
1M ago
ATOS
Atossa Therapeutics announces $16.5M registered direct offering
PremiumThe Fly
Atossa Therapeutics announces $16.5M registered direct offering
1M ago
ATOS
Atossa: Buy Rating Reiterated as DMD and Oncology Pipeline Advances; $20 Price Target Unchanged
PremiumRatings
Atossa: Buy Rating Reiterated as DMD and Oncology Pipeline Advances; $20 Price Target Unchanged
1M ago
ATOS
Jason McCarthy Reiterates Buy on Endoxifen Developer, Lifting 12-Month Price Target to $20 on Strong ER+ Breast Cancer Data and Pipeline Expansion
PremiumRatingsJason McCarthy Reiterates Buy on Endoxifen Developer, Lifting 12-Month Price Target to $20 on Strong ER+ Breast Cancer Data and Pipeline Expansion
1M ago
ATOS
Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year
Premium
The Fly
Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year
2M ago
ATOS
Atossa Therapeutics Shareholders Approve Proposals at 2026 Meeting
Premium
Company Announcements
Atossa Therapeutics Shareholders Approve Proposals at 2026 Meeting
2M ago
8K
ATOS
Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial
PremiumThe Fly
Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial
2M ago
ATOS
Atossa Therapeutics says FDA grants RPD to (Z)-endoxifen to treat MAS
PremiumThe Fly
Atossa Therapeutics says FDA grants RPD to (Z)-endoxifen to treat MAS
2M ago
ATOS
Atossa: Patent De‑Risking and Endoxifen Franchise Optionality Support Buy Rating and Upside to Target Price
PremiumRatings
Atossa: Patent De‑Risking and Endoxifen Franchise Optionality Support Buy Rating and Upside to Target Price
3M ago
ATOS
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights
PremiumCompany Announcements
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights
3M ago
8K
ATOS
Atossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright
PremiumThe FlyAtossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright
4M ago
ATOS
Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
Premium
The Fly
Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
4M ago
ATOS
Atossa Therapeutics announces addition of two biopharma executives to team
Premium
The Fly
Atossa Therapeutics announces addition of two biopharma executives to team
4M ago
ATOS
VTI ETF Inflows Hold Steady Despite AI Sell-Off – 2/24/26
PremiumMarket News
VTI ETF Inflows Hold Steady Despite AI Sell-Off – 2/24/26
5M ago
L
CLB
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26
PremiumMarket News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26
5M ago
CLB
IMA
Atossa Therapeutics Launches New $50 Million ATM Program
PremiumCompany Announcements
Atossa Therapeutics Launches New $50 Million ATM Program
5M ago
8K
ATOS
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/20/26
PremiumMarket News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/20/26
5M ago
L
CLB
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/19/26
PremiumMarket NewsVanguard Total Stock Market ETF (VTI) Daily Snapshot—2/19/26
5M ago
L
CLB
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
Premium
Company Announcements
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
5M ago
8K
ATOS
Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum
Premium
The Fly
Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum
5M ago
ATOS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >